Bristol Myers Squibb Company
BMY-
Karuna Therapeutics soared 47.4% to $317.22 after Bristol Myers agreed to pay $330 per share, or $14 billion, to acquire the maker of the schizophrenia drug KarXT.
The U.S. Food and Drug Administration has accepted KarXT for a review.
Bristol-Myers declined 1.7% to $50.36.
Dec 22, 2023 -
Bristol-Myers Squibb dropped 5.7% to $53.40 after the company reported quarterly earnings.
The pharmaceutical company said sales of its popular blood cancer drug, Revlimid, were down because of rising competition from generic drugs.
Revenue in the third quarter declined 2% to $10.96 billion from $11.2 billion, net income rose to $1.9 billion from $1.2 billion, and diluted earnings per share advanced to 93 cents from 75 cents a year ago.
Revlimid worldwide revenues fell 41% from a year ago to $1.4 billion, primarily due to generic competition and an increase in the number of patients receiving free drug products from the Bristol Myers Squibb Patient Assistance Foundation.
The company reiterated its full-year 2023 revenue decline to a low single-digit and narrowed its earnings per share range to between $3.68 and $3.83 from the previous range between $3.72 and $4.02.
Oct 26, 2023 -
Bristol-Myers Squibb Co edged up 0.1% to $56.68 after the company agreed to acquire San Diego-based Mirati Therapeutics for $58 a share or $4.8 billion on Sunday evening.
The company also agreed to as much as additional $1 billion in milestone payments.
With the purchase of Mirati, Bristol-Myers expanded its cancer treatment portfolio after Mirati's non-small cell lung cancer drug Krazati was approved by the U.S. FDA.
Oct 10, 2023
|
|
| |
|
| Trading Volume | 337,218 |
|
|
62.01 - 40.13 |
| Market Cap Full | $ 101.2B |
Quarterly +
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Q1 | -0% | 5.3% | -3.7% | 17.1% |
| Q2 | - | -21.6% | -7.8% | 5.4% |
| Q3 | - | 4.8% | -9.2% | -8.4% |
| Q4 | - | 3.5% | -11.4% | 2% |
Monthly +
| J | F | M | A | M | J | J | A | S | O | N | D |
| 2025 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | |||||||||||
| -4.8 | 3.9 | 6.5 | -9.4 | -16 | 1 | 14.3 | 4.8 | - | - | - | -4.5 |
| 2023 | |||||||||||
| 1 | -5.1 | 0.5 | -3.6 | -3.5 | -0.8 | -2.7 | -0.9 | -5.8 | -11.3 | -4.2 | 3.9 |
| 2022 | |||||||||||
| 4 | 5.9 | 6.4 | 3.1 | -0.2 | 2.5 | -4.2 | -8.6 | 4.7 | 9.8 | 3.6 | -10.4 |
| 2021 | |||||||||||
| -0.6 | 1.2 | 2.2 | -2 | 6.4 | 0.5 | 2.3 | -1.5 | -11.5 | -1.3 | -8.2 | 16.3 |
| 2020 | |||||||||||
| -1.1 | -8.5 | -3.6 | 9.1 | -1.8 | -1.5 | -0.2 | 6 | -2.9 | -4 | 7.6 | -1.4 |
EPS
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Q1 | 1.1 | 0.6 | 0.9 | -0.3 |
| Q2 | 1 | 0.7 | 0.5 | -0 |
| Q3 | 0.9 | 0.8 | 0.7 | 0.8 |
| Q4 | 0 | 1 | 1.1 | -4.4 |
| A | 2.99 | 3 | 3.1 | -4 |